Европейски съюз - френски - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, propionate de fluticasone - asthme - les médicaments pour les maladies respiratoires obstructives, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Европейски съюз - френски - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - asthme - les médicaments pour les maladies respiratoires obstructives, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Европейски съюз - френски - EMA (European Medicines Agency)

almirall, s.a. - tirbanibulin - kératose actinique - antibiotiques et chimiothérapies à usage dermatologique - klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (olsen grade 1) of the face or scalp in adults.

Европейски съюз - френски - EMA (European Medicines Agency)

koanaa healthcare gmbh - l'imatinib mésilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - agents antinéoplasiques - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. les patients qui ont une faible ou très faible risque de récidive ne doit pas recevoir de traitement adjuvant. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. sauf dans les pays nouvellement diagnostiqué en phase chronique de la lmc, il n'y a pas d'essais contrôlés à démontrer un bénéfice clinique ou l'augmentation de la survie pour ces maladies.

Европейски съюз - френски - EMA (European Medicines Agency)

laboratorios lesvi s.l. - fumarate de diméthyle - la sclérose en plaques, sep récurrente-rémittente - immunosuppresseurs - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Европейски съюз - френски - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - immunosuppresseurs - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Франция - френски - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

arrow generiques - sumatriptan 50 mg sous forme de : succinate de sumatriptan - comprimé - pour un comprimé > sumatriptan 50 mg sous forme de : succinate de sumatriptan - analgésiques : agonistes sélectifs des récepteurs 5-ht1 - classe pharmacothérapeutique : analgésiques : agonistes sélectifs des récepteurs 5-ht1 - code atc : n02cc01.chaque comprimé oblong de sumatriptan arrow contient une dose unique de sumatriptan qui appartient à la classe des médicaments appelés triptans (aussi connus sous le nom d’agoniste des récepteurs 5-ht1).sumatriptan arrow est indiqué dans le traitement de la crise de migraine.les céphalées migraineuses peuvent être dues à une dilatation temporaire des vaisseaux sanguins. il est envisagé que sumatriptan arrow contracte ces vaisseaux sanguins. cela a pour effet le soulagement de la migraine et des autres symptômes de la migraine, comme les nausées ou les vomissements et la sensibilité à la lumière ou au bruit.

Канада - френски - Health Canada

guerbet - iode (huile éthiodée) - liquide - 380mg - iode (huile éthiodée) 380mg - roentgenography

Европейски съюз - френски - EMA (European Medicines Agency)

shire pharmaceutical contracts limited - delta de l'époétine - kidney failure, chronic; anemia - préparations antianémiques - dynepo est indiqué pour le traitement de l'anémie symptomatique associée à l'insuffisance rénale chronique (irc) chez les patients adultes. il peut être utilisé chez les patients dialysés et chez les patients non dialysés.

Европейски съюз - френски - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - ziconotide - injections, spinal; pain - analgésiques - le ziconotide est indiqué pour le traitement de la douleur chronique sévère chez les patients nécessitant une analgésie intrathécale (it).